Name:Min Liu

Address:Department of Pharmacology, Shandong University School of Medicine, Jinan 250012,China

Work Phone:86-0531-88382605

Mobile Phone:15065412820

E-mail:liuweimin@sdu.edu.cn

EDUCATION:

9, 2014-12, 2017 Department of Pharmacology, Shandong University School of

Medicine,China.

Ph.D. Pharmacology

Thesis topic: Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling

9, 2011-7, 2014 School of Pharmaceutical Sciences, Sun Yat-Sen University,China.

M.S. Pharmacology

Thesis topic: Initial research of PARP-1 inhibitors protect cardiac hypertrophy induced by AngⅡ

9, 2007-7, 2011 Marine College, Shandong University School of Medicine,China.

B.S. Pharmacy

WORK EXPERIENCE:

03, 2018-now Department of Pharmacology, Shandong University School of Medicine, Jinan, Shandong

Province,China, 250012

Research focus: The pathogensis of chronic kidney disease.

PUBLICATIONS:

1.Min Liu, Kaili Liang, Junhui Zhen, Meng Zhou, Xiaojie Wang, Ziying Wang, Xinbing Wei, Yan Zhang,Yu Sun, Zhuanli Zhou, Hua Su, Chun Zhang, Ningjun Li, Chengjiang Gao, Jun Peng & Fan Yi. Sirt6 Deficiency Exacerbates Podocyte Injury and Proteinuria through Targeting Notch Signaling.Nature communications.2017.8(1)413.

This article has been recommended to F1000.

2.Min Liu, Zhe Li et al, AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngⅡ-induced hypertrophy,Molecular and Cellular Endocrinology, 2014, 392: 14-22.

3.Min Liu, Jiantao Ye et al, Salvianolic acid B protects cardiomyocytes from angiotensin Ⅱ-induced hypertrophy via inhibition of PARP-1,Biochemical and Biophysical Research Communications, 2014, 444：346–353.

Foundations：

1.National Natural Science Foundation ofChina, 81800645, 2019.01-2021.12.

2.ShandongProvinceNatural Science Foundation, ZR201807060667, 2019.07- 2022-06.